Skip to content
Screener

D&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.96B+0.8%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$270.8M-0.4%
Treace Medical Concepts, Inc. logo
Treace Medical Concepts, Inc.TMCI
$1.89M-26.7%
ESAB logo
ESABESAB
$27.87M+44.0%
OrthoPediatrics logo
OrthoPediatricsKIDS
$5.71M+10.4%
Bioventus logo
BioventusBVS
$10.95M-9.2%

Segments

By segment

See full
Reconstructive$23.69M-1.1%
Prevention & Recovery$5.13M

Other financials

Income statement

See full
Revenue$582.8M+3.2%
Gross profit$359.2M+7.3%
Operating income$17.4M+204%
Net income-$1.2M+96.8%
EPS (diluted)-$0.02+96.9%

Balance sheet

See full
Cash & equivalents$12.6M-71.5%
Total debt$1.3B-6.4%
Total equity$1.5B-42.7%
Total assets$3.8B-25.0%

Cash flow

See full
Operating cash flow$75.0M+57.1%
CapEx$43.9M-1.1%
Free cash flow$31.1M

Valuation

See full
Market cap$1.53B-5.5%
Enterprise value$2.83B-4.9%
P/S0.7×-0.1×

Profitability

See full
Gross margin61.1%+3.5pp
Operating margin-45.1%+19.4pp
Net margin-48%+17.7pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-54.3%+672pp
Debt / equity0.9×+0.3×
Current ratio-0.3×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Enovis’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001420800-26-000035
Line itemSix Months Ended / July 3, 2026Six Months Ended / July 4, 2025
Cash flows from operating activities:
Net loss$(9,486)$(92,253)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization144,381142,986
Stock-based compensation expense17,71816,075
Non-cash interest expense3,5063,203
Fair value loss on contingent acquisition shares1,787
Deferred income tax benefit(42,200)(3,673)

Item 1. Financial Statements

FAQ

What is Enovis's D&A?
Enovis (ENOV) reported D&A of $71.03M in Q2 2026.
How has Enovis's D&A changed year-over-year?
Enovis's D&A decreased by 0.7% year-over-year, from $71.55M to $71.03M.
What is the long-term trend for Enovis's D&A?
Over 4 years (2021 to 2025), Enovis's D&A has grown at a 2.9% compound annual growth rate (CAGR), from $262.92M to $294.38M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Enovis's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude